CoChat

Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background: The duodenum has become a metabolic treatment target through bariatric surgery learnings and the specific observation that bypassing, excluding or altering duodenal nutrient exposure elicits favourable metabolic changes. Duodenal mucosal resurfacing (DMR) is a novel endoscopic procedure that has been shown to improve glycaemic control in people with type 2 diabetes mellitus (T2D) irrespective of body mass index (BMI) changes. DMR involves catheter-based circumferential mucosal lifting followed by hydrothermal ablation of duodenal mucosa. This multicentre study evaluates safety and feasibility of DMR and its effect on glycaemia at 24 weeks and 12 months. Methods: International multicentre, open-label study. Patients (BMI 24–40) with T2D (HbA1c 59–86 mmol/mol (7.5%–10.0%)) on stable oral glucose-lowering medication underwent DMR. Glucose-lowering medication was kept stable for at least 24 weeks post DMR. During follow-up, HbA1c, fasting plasma glucose (FPG), weight, hepatic transaminases, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), adverse events (AEs) and treatment satisfaction were determined and analysed using repeated measures analysis of variance with Bonferroni correction. Results: Forty-six patients were included of whom 37 (80%) underwent complete DMR and 36 were finally analysed; in remaining patients, mainly technical issues were observed. Twenty-four patients had at least one AE (52%) related to DMR. Of these, 81% were mild. One SAE and no unanticipated AEs were reported. Twenty-four weeks post DMR (n=36), HbA1c (−10±2 mmol/mol (−0.9%±0.2%), p<0.001), FPG (−1.7±0.5 mmol/L, p<0.001) and HOMA-IR improved (−2.9±1.1, p<0.001), weight was modestly reduced (−2.5±0.6 kg, p<0.001) and hepatic transaminase levels decreased. Effects were sustained at 12 months. Change in HbA1c did not correlate with modest weight loss. Diabetes treatment satisfaction scores improved significantly. Conclusions: In this multicentre study, DMR was found to be a feasible and safe endoscopic procedure that elicited durable glycaemic improvement in suboptimally controlled T2D patients using oral glucose-lowering medication irrespective of weight loss. Effects on the liver are examined further. Trial registration number: NCT02413567

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2019-318349

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Enrolment flow diagram. *Four subjects were excluded based on two criteria. BMI, body mass index; DMR, duodenal mucosal resurfacing; HbA1c, glycated haemoglobin.
Figure 1 Enrolment flow diagram. *Four subjects were excluded based on two criteria. BMI, body mass index; DMR, duodenal mucosal resurfacing; HbA1c, glycated haemoglobin.CC BY-NC · PubMed Central
Figure 2 Change in HbA1c after DMR over 12 months follow-up. (A) Primary endpoint: mean difference ±SE in HbA1c at 24 weeks and 12 months when compared with baseline after a single endoscopic DMR procedure. Analysis with paired t-test. (B) Mean ±SE HbA1c during follow-up up to 12 months after single DMR. ANOVA repeated measurements analysis with Bonferroni correction to apply a more rigorous data analysis. n=36. ‡P<0.0001 when compared with baseline (paired t-test). * P< 0.01 when compared with baseline (ANOVA repeated measurements, Bonferroni-adjusted p value). DMR, duodenal mucosal resurfacing; HbA1C, glycated haemoglobin.
Figure 2 Change in HbA1c after DMR over 12 months follow-up. (A) Primary endpoint: mean difference ±SE in HbA1c at 24 weeks and 12 months when compared with baseline after a single endoscopic DMR procedure. Analysis with paired t-test. (B) Mean ±SE HbA1c during follow-up up to 12 months after single DMR. ANOVA repeated measurements analysis with Bonferroni correction to apply a more rigorous data analysis. n=36. ‡P<0.0001 when compared with baseline (paired t-test). * P< 0.01 when compared with baseline (ANOVA repeated measurements, Bonferroni-adjusted p value). DMR, duodenal mucosal resurfacing; HbA1C, glycated haemoglobin.CC BY-NC · PubMed Central
Figure 3 Changes in FPG, insulin sensitivity and weight after DMR over 12 months follow-up. Data represent mean ±SE changes after a single endoscopic DMR procedure in (A) FPG, (B) HOMA-IR and (C) weight. n=36. Analysis with ANOVA for repeated measurements with Bonferroni correction. *Indicates a significant difference (Bonferroni adjusted p value < 0.01) when compared with baseline values. ANOVA, analysis of variance; DMR, duodenal mucosal resurfacing; FPG, fasting plasma glucose; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance.
Figure 3 Changes in FPG, insulin sensitivity and weight after DMR over 12 months follow-up. Data represent mean ±SE changes after a single endoscopic DMR procedure in (A) FPG, (B) HOMA-IR and (C) weight. n=36. Analysis with ANOVA for repeated measurements with Bonferroni correction. *Indicates a significant difference (Bonferroni adjusted p value < 0.01) when compared with baseline values. ANOVA, analysis of variance; DMR, duodenal mucosal resurfacing; FPG, fasting plasma glucose; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance.CC BY-NC · PubMed Central
Figure 4 Change in ALT levels after DMR over 12 months follow-up. Post-DMR mean ±SE change in ALT levels. n=36. Analysis with ANOVA for repeated measurements with Bonferroni correction. *Indicates a significant difference (Bonferroni-adjusted p value <0.01) when compared with baseline values. ALT, alanine transaminase; ANOVA, analysis of variance; DMR, duodenal mucosal resurfacing.
Figure 4 Change in ALT levels after DMR over 12 months follow-up. Post-DMR mean ±SE change in ALT levels. n=36. Analysis with ANOVA for repeated measurements with Bonferroni correction. *Indicates a significant difference (Bonferroni-adjusted p value <0.01) when compared with baseline values. ALT, alanine transaminase; ANOVA, analysis of variance; DMR, duodenal mucosal resurfacing.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 207

Metadata

Authors
van Baar, A. C. G., Holleman, F., Crenier, L., Haidry, R., Magee, C., Hopkins, D., Rodriguez Grunert, L., Galvao Neto, M., Vignolo, P., Hayee, B., Mertens, A., Bisschops, R., Tijssen, J., Nieuwdorp, M., Guidone, C., Costamagna, G., Devière, J., & Bergman, J. J. G. H. M.
Affiliations
  • Gastroenterology and Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Erasmus Hospital (BE)
  • University College Hospital (GB)
  • Kings Health Partners (GB)
  • CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
  • Bariatric Endoscopy Service, Gastro Obeso Center, Sao Paulo, Brazil
  • King's College Hospital (GB)
  • KU Leuven (BE)
  • Agostino Gemelli University Polyclinic (IT)
  • Gastroenterology, Erasme University Hospital, Brussels, Belgium
Corresponding author
Bergman, Jacques J G H M
Venue
Gut
Publisher
BMJ
Published
2019-07-22
Volume
69
Issue
2
Pages
295-303
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2964114017
Cited by
201
References
23
Citations by year
2026: 10 · 2025: 25 · 2024: 32 · 2023: 25 · 2022: 33 · 2021: 35 · 2020: 35 · 2019: 5
FWCI
25.77
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, cc-by-nc)
  • Lirias (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Fractyl Laboratories
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
duodenal mucosal resurfacing, type 2 diabetes, endoscopic treatment, glycemic control, HbA1c, fasting blood glucose, insulin resistance, HOMA-IR, weight loss, hepatic transaminases, adverse events, duodenal bypass, HbA1c reduction
MeSH terms
Endoscopic Mucosal Resection, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Duodenoscopy, Duodenum, Feasibility Studies, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Prospective Studies, Patient Satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. https://app.cochat.ai/papers/10.1136/gutjnl-2019-318349
The paper
van Baar, A. C. G., Holleman, F., Crenier, L., Haidry, R., Magee, C., Hopkins, D., Rodriguez Grunert, L., Galvao Neto, M., Vignolo, P., Hayee, B., Mertens, A., Bisschops, R., Tijssen, J., Nieuwdorp, M., Guidone, C., Costamagna, G., Devière, J., & Bergman, J. J. G. H. M. (2020). Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. https://doi.org/10.1136/gutjnl-2019-318349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.